Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine

被引：0

作者：

David W. Dodick

Giorgio Sandrini

Paul Williams

机构：

[1] Mayo Clinic,Department of Neurology

[2] University Center for Adaptive Disorders and Headache,undefined

[3] IRCCS C. Mondino Foundation,undefined

[4] University of Pavia,undefined

[5] PAREXEL International,undefined

来源：

CNS Drugs | 2007年 / 21卷

关键词：

Migraine; Sumatriptan; Zolmitriptan; Rizatriptan; Triptan;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Objective: To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT1B/1D receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan, but not frovatriptan) in order to provide a rationale for the use of the rate of patients who are SPF plus no AE (SNAE) as an endpoint in trials of medications for acute migraine.

引用

页码：73 / 82

页数：9

共 50 条

[1] Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine
Dodick, David W.
Sandrini, Giorgio
Williams, Paul
[J]. CNS DRUGS, 2007, 21 (01) : 73 - 82
[2] Sumatriptan powder delivered by a novel nasal device provides excellent sustained pain-free plus no adverse events scores in acute migraine
Docekal, P.
Djupesland, P. G.
[J]. CEPHALALGIA, 2009, 29 : 15 - 15
[3] Sumatriptan powder delivered by the OptiNose™ nasal device provide excellent sustained pain-free plus no adverse events scores in acute migraine
Djupesland, P. G.
Docekal, P.
[J]. JOURNAL OF NEUROLOGY, 2009, 256 : S105 - S105
[4] Is sustained pain freedom and no adverse events a clinically relevant endpoint in acute migraine treatment?
Tfelt-Hansen, Peer
[J]. CEPHALALGIA, 2011, 31 (11) : 1240 - 1240
[5] Acute migraine therapy with frovatriptan vs. sumatriptan: comparison based on sustained pain-free response with no adverse events
Campbell, J.
Harper, S.
Hu, X.
[J]. CEPHALALGIA, 2009, 29 : 18 - 19
[6] Almotriptan increases sustained pain-free outcomes in acute migraine: Results from three controlled clinical trials
Dodick, DW
[J]. HEADACHE, 2002, 42 (01): : 21 - 27
[7] Evaluation of combination therapy (sumatriptan/naproxen sodium) versus monotherapy for the acute treatment of migraine using a novel clinical endpoint: Sustained pain free and no adverse events
Landy, Stephen
White, Jonathan D.
Lener, Shelly E.
McDonald, Susan A.
[J]. NEUROLOGY, 2008, 70 (11) : A353 - A354
[8] Early intervention with almotriptan improves sustained pain-free response in acute migraine
Mathew, NT
[J]. HEADACHE, 2003, 43 (10): : 1075 - 1079
[9] Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan
Dodick, David W.
Kost, James
Assaid, Christopher
Lines, Christopher
Ho, Tony W.
[J]. CEPHALALGIA, 2011, 31 (03) : 296 - 300
[10] Almotriptan increases pain-free status in patients with acute migraine treated in placebo-controlled clinical trials
Mathew, NT
[J]. HEADACHE, 2002, 42 : S32 - S37

← 1 2 3 4 5 →